Science prize awarded to DDr. Klaus Podar
In the auditorium Grafenegg on Monday evening the prestigious science prizes of the province of Lower Austria were awarded.
For more than 55 years, the province of Lower Austria has been awarding these for outstanding scientific achievements. Researchers are awarded for their theses or scientific projects. The highest award, the Würdigungspreis, recognizes an overall scientific work of supraregional significance. The two appreciation prizes were awarded to the physician Klaus Podar and the art historian Huberta Weigl.
Priv.-Doz. Mag. DDr. Klaus Podar did research for almost ten years at an institute for cancer cure in Boston, where he started his teaching activities in the field of medical oncology. Currently, he impressively combines the fields of research, teaching and therapy as a senior physician at the University Hospital Krems and as head of the Molecular Oncology and Hematology Group at the Karl Landsteiner University of Health Sciences.
Together with his research group "Molecular Oncology/Hematology", Klaus Podar is involved, among other things, in researching signaling pathways within the tumor microenvironment and in translating these findings into future therapeutic approaches, especially in the areas of multiple myeloma and breast cancer. He is entrusted with the establishment of the oncological research area at the Karl Landsteiner University of Health Sciences and leads the inter-institutional project "ACCESS POINT" for basic oncological research (APOG-NOo).
The award is endowed with 11.000,-- Euro.
SUPPORT IN RESEARCH: The research group Molecular Hematology and Oncology, focuses on the development of innovative therapeutic anti-cancer agents. The focus is on the investigation of molecular basis of oncological/hematological tumor diseases and the development of new diagnostics, therapeutics and innovative therapeutic strategies derived therefrom.
Even small contributions help to purchase necessary consumables (chemicals, antibodies, assay kits, plasticware), and thus advance the progress of oncological/hematological research for the benefit of our tumor patients. Are you interested in supporting the Molecular Oncology and Hematology Group?Here you can find more information on support opportunities in the research
